reports
Esperion to Participate in Jefferies Global Healthcare Conference - Lo...
Esperion to Participate in Jefferies Global Healthcare Conference - London ANN ARBOR, Mich., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will present at the Jefferies Global Healthcare Conference – London on November 18, 2025, at 8:00 a.m. GMT (3:00 a.m. ET). The live webcast can be accessed on the investor and media section of the Esperion . Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website for approximately 90 days. Esperion TherapeuticsEsp...
Esperion to Host Virtual Investor Key Opinion Leader Event Highlightin...
Esperion to Host Virtual Investor Key Opinion Leader Event Highlighting Significant Unmet Need in Statin Intolerance on Tuesday, November 11, 2025, at 2:00 p.m. ET. – Leading Cardiovascular Physician Experts to Explore Real-World Challenges and Impact on Patient Outcomes – ANN ARBOR, Mich., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will host a virtual key opinion leader (KOL) event for investors to discuss the clinical and real-world challenges of statin intolerance, its impact on patient outcomes, and the Company’s continued commitment to addressing th...
Esperion Announces New Analyses from CLEAR Outcomes to be Presented at...
Esperion Announces New Analyses from CLEAR Outcomes to be Presented at the American Heart Association (AHA) Scientific Sessions 2025 ANN ARBOR, Mich., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that an oral presentation and a poster presentation have been accepted for presentation at the AHA Scientific Sessions 2025 in New Orleans, LA, November 7-10, 2025. Oral Presentation Bempedoic acid monotherapy, LDL cholesterol, and cardiovascular events: a secondary analysis of the CLEAR Outcomes trialNovember 9, 2025, 9:45 – 11:00 AM CSTPresenter: Carolina Pires Zin...
Esperion to Report Third Quarter 2025 Financial Results on November 6
Esperion to Report Third Quarter 2025 Financial Results on November 6 ANN ARBOR, Mich., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report third quarter 2025 financial results before the market opens on Thursday, November 6, 2025. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates. A live audio webcast can be accessed on the investor and media section of the Esperion . Access to the webcast replay will be available approximately two hours after completion of the call ...
Esperion Nominates ESP-2001 as Preclinical Development Candidate for T...
Esperion Nominates ESP-2001 as Preclinical Development Candidate for Treatment of Primary Sclerosing Cholangitis – Highly-Specific Allosteric ACLY Inhibitor Designed to Target Liver and Bile Duct Injury, Inflammation, and Fibrosis Associated with Primary Sclerosing Cholangitis (PSC) and Related Diseases – – ESP-2001 Has the Potential to Meaningfully Impact the Progression of PSC, a Disease with No Approved Treatments – ANN ARBOR, Mich., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the nomination of ESP-2001, the Company’s highly-specific allosteric ATP citra...
Esperion Announces Pricing of Public Offering of Common Stock
Esperion Announces Pricing of Public Offering of Common Stock ANN ARBOR, Mich., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (“Esperion”) (Nasdaq: ESPR), a commercial stage biopharmaceutical company that focuses on developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C), today announced the pricing of an underwritten public offering of 30,000,000 shares of its common stock at a public offering price of $2.50 per share. In addition, Esperion has granted the underwrit...
Esperion Announces Proposed Public Offering of Common Stock
Esperion Announces Proposed Public Offering of Common Stock ANN ARBOR, Mich., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (“Esperion”) (Nasdaq: ESPR), a commercial stage biopharmaceutical company that focuses on developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C), today announced that it has commenced an underwritten public offering of shares of its common stock. Esperion also intends to grant the underwriters a 30-day option to purchase up to an additional fif...
Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy’s Lab...
Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy’s Laboratories, Not to Market Generic Versions of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Prior to April 19, 2040 ANN ARBOR, Mich., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Dr. Reddy’s Laboratories, Inc. and its affiliate Dr. Reddy’s Laboratories Ltd. (together, Dr. Reddy’s Laboratories). This agreement resolves the patent litigation brought by Esperion against Dr. Reddy’s Laboratories in response to Dr. Redd...
Esperion Partner Otsuka Receives Regulatory Approval to Market NEXLETO...
Esperion Partner Otsuka Receives Regulatory Approval to Market NEXLETOL® in Japan for the Treatment of Hypercholesterolemia Third Largest Global Market for Cardiovascular Prevention Represents Significant Global Growth Opportunity for NEXLETOL ANN ARBOR, Mich., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that Otsuka Pharmaceutical Co., Ltd. (Otsuka), the Company’s partner for the development and commercialization of NEXLETOL® (bempedoic acid) tablets in Japan, has received approval from the Japanese Ministry of Health, Labour and Welfare to market NEXLETOL...
Esperion’s Bempedoic Acid Receives Level 1a Recommendation in Updated ...
Esperion’s Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias – Bempedoic Acid Receives Strongest Endorsement from ESC/EAS Guidelines Based on Compelling and Practice-Changing Evidence – – Guideline Recognition of ‘Strike Early and Strike Strong’ Approach with Early Combination Lipid-Lowering Therapy Affirms Continued Development of Company’s Oral Triple Combination Therapies in U.S. – ANN ARBOR, Mich., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today welcomed the inclusion of bempedoic acid as the only n...
Esperion to Participate in Upcoming September Investor Conferences
Esperion to Participate in Upcoming September Investor Conferences ANN ARBOR, Mich., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the following webcasted investor events during the month of September, which can be found on our investor relations . Cantor Global Healthcare Conference in New York on September 3, 2025, at 9:45 a.m. ET. H.C. Wainwright 27th Annual Global Investment Conference in New York on September 8, 2025, at 2:00 p.m. ET. Live webcasts can be accessed on the investor and media section of the Esperio...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) ANN ARBOR, Mich., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on August 5, 2025, the Company granted 12 new employees 73,500 restricted stock units (RSUs) under Esperion’s 2017 Inducement Equity Incentive Plan. The 2017 Inducement Equity Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Esperion (or following a bona fide period of non-employment), as an inducement material to such indivi...
Esperion Reports Second Quarter 2025 Financial Results and Provides Bu...
Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update – Q2 2025 Total Revenue Grew 12% Y/Y to $82.4 Million – – Q2 2025 U.S. Net Product Revenue Grew 42% Y/Y to $40.3 Million – – Total Retail Prescription Equivalents Increased 10% from First Quarter – – Reached Settlement Agreements with Three ANDA Filers Not to Market Generic Versions of NEXLETOL® (bempedoic acid) Prior to 2040 – – First Quarter of Operating Income from Ongoing Business with Plans for Sustainable Profitability Starting in Q1 2026 – – Conference Call and Webcast Today at 8:00 a.m...
Esperion to Report Second Quarter 2025 Financial Results on August 5
Esperion to Report Second Quarter 2025 Financial Results on August 5 ANN ARBOR, Mich., July 22, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report second quarter 2025 financial results before the market opens on Tuesday, August 5, 2025. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates. A live audio webcast can be accessed on the investor and media section of the Esperion . Access to the webcast replay will be available approximately two hours after completion of the call and...
Esperion Reaches Settlement Agreement with Third ANDA Filer Not to Mar...
Esperion Reaches Settlement Agreement with Third ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040 ANN ARBOR, Mich., July 08, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Accord Healthcare Inc. This agreement resolves the patent litigation brought by Esperion against Accord Healthcare Inc. in response to Accord Healthcare Inc’s Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of NEXLETOL prior to the expiration of the applicable patents....
Esperion Appoints Craig Thompson to Board of Directors
Esperion Appoints Craig Thompson to Board of Directors Brings More Than Twenty Years of Biopharmaceutical Leadership Experience ANN ARBOR, Mich., July 01, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it has appointed Craig Thompson, Chief Executive Officer of Cerevance, to its Board of Directors. Mr. Thompson will serve as an independent director. With Mr. Thompson’s appointment, Esperion’s Board of Directors now comprises eight members. “We are thrilled to welcome Craig to our Board of Directors. With more than two decades of biopharmaceutical industry leadership a...
Esperion Reaches Settlement Agreement with Second ANDA Filer Not to Ma...
Esperion Reaches Settlement Agreement with Second ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040 ANN ARBOR, Mich., June 02, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Hetero USA, Inc. and its affiliates Hetero Labs Limited, Hetero Labs Limited Unit-V, and Honour Lab Limited (together, Hetero USA). This agreement resolves the patent litigation brought by Esperion against Hetero USA in response to Hetero USA’ s Abbreviated New Drug Application (ANDA) seeking approval to...
Esperion to Participate in Upcoming June Investor Conferences
Esperion to Participate in Upcoming June Investor Conferences ANN ARBOR, Mich., May 20, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the following webcasted investor events during the month of June, which can be found on our investor relations . Jefferies Global Healthcare Conference in New York on June 4, 2025, at 1:25 p.m. ET. Goldman Sachs Global Healthcare Conference in Miami on June 9, 2025, at 10:40 a.m. ET. Live webcasts can be accessed on the investor and media section of the Esperion . Access to the webcast replay w...
Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Ge...
Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040 ANN ARBOR, Mich., May 12, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Micro Labs USA, Inc. and its affiliate Micro Labs Limited (together, Micro Labs). This agreement resolves the patent litigation brought by Esperion against Micro Labs in response to Micro Labs’ Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of NEXLETOL prior to the expiratio...
Esperion to Participate in H.C. Wainwright’s 3rd Annual BioConnect Inv...
Esperion to Participate in H.C. Wainwright’s 3rd Annual BioConnect Investor Conference ANN ARBOR, Mich., May 09, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20, 2025, at 10 a.m. ET. The live webcast can be accessed on the investor and media section of the Esperion . Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website for approximately 90 days. Esperio...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.